Focal Chondral Defect in Femoro-tibial Compartment of the Knee Joint
Conditions
Keywords
cartilage tissue engineering, hyaluronan, hyaluronic acid
Brief summary
The two-layer bioresorbable HYTOP® matrix consists of an upper layer of highly purified porcine splint-skin which contains natural pores, and a lower layer of highly purified collagen fleece containing hyaluronan (HA). In this study, the medical device will be used and evaluated in a one-step procedure combining microfracturing with surgical implantation of HYTOP®. HYTOP® will support haemostasis in the articular cartilage defect, act as a support for cell growth and as a three-dimensional scaffold for cell differentiation. HYTOP® will protect the underlying tissue after cartilage debridement and/or microfracturing of the subchondral bone. The primary working hypothesis is that HYTOP® is safe and suitable as a cell-free matrix to support haemostasis, as a cover for the cartilage lesion and eventually to enhance cartilage regeneration in a one-step surgical procedure.
Interventions
DEVICEHYTOP®
HYTOP® will be implanted once during surgery.
Sponsors
TRB Chemedica AG
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Male and female patients between 18 and 50 years of age. * Good general health condition. * Signed written informed consent. * General anaesthesia is justifiable for the patient from the medical point of view. * Focal chondral defects involving the femorotibial compartment of the knee joint localised in only one compartment and not larger than the size of one HYTOP® patch. * Isolated one-sided chondral lesion. * Cartilage defect classified as Outerbridge grade 3 or 4. * Chondral lesions not exceeding through the subchondral bone (intact subchondral bone). * Nearly intact chondral structure surrounding the defect, specifically Outerbridge grade 2 or less. * Corresponding joint area classified with maximum Outerbridge grade 2. * Clinical symptoms in the target joint (pain on walking 100 m of more than 4 on an 11-point numerical scale or swelling or locking or 'giving way'). * Ensured compliance of subjects over the whole study period.
Exclusion criteria
* Treatment with any investigational product within 4 weeks prior to study entry. * Patients with known hypersensitivity to the constituents of the product or any component or procedure used in the study. * Patients with previous treatment of the study relevant defect site. * Cartilage lesion is not intact shouldered, has bipolar or corresponding involvement or bipolar 'kissing' lesions. * Necessity of cartilage repair treatment at bilateral joints. * Patients with meniscus lesions, total or partial (more than 1/3 of total volume) resected meniscus, limited joint mobility, varus/valgus joint malalignment of more than 5 degrees or insufficient ligament support. * Inflammatory joint diseases (e.g. rheumatoid arthritis, Bechterew disease, chondromatosis). * Infection at study relevant site. * Osteoarthritis, arthrofibrosis or haematopoetic related diseases. * Study relevant metabolic disease, adipositas (BMI equal to or greater 30 kilogram per square meter). * Study relevant neoplastic, neurological or mental illness. * Study relevant autoimmune disease. * Patients with elevated risk of bleeding. * Recent history of drug and/or alcohol abuse (within the last 6 months). * Pregnant or lactating females. * Participants of childbearing age (pre-menopausal) who do not accept the use of methods of birth control with pearl index more than 1% (e.g. oral contraceptives, vaginal ring, hormone-releasing intrauterine device (IUD), implants, depot syringes, hormone patch, double barrier method, tubal ligation, vasectomised partner,…) during the treatment period and the first 12 weeks of follow-up period. * Subjects unable to understand informed consent or having a high probability of non compliance to the study procedures and/or non completion of the study according to investigator's judgement (e.g. illiteracy, insufficient knowledge of local language). * Subjects not capable of contracting and of understanding the nature, risks, significance and implications of the clinical investigation and unable to form a rational intention in the light of these facts. * Low probability of compliance with after-care rehabilitation scheme. * Forbidden concomitant treatment affecting the evaluation of study parameters (e.g. oral intake of chondroitin sulfate, glucosamine, piascledine, other i.a. treatments like depot corticosteroids or arthroscopic procedures).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of adverse events with causal relationship to the investigational medical device. | Up to 2 years (plus or minus 14 days) after surgery. | Adverse events with causal relationship to the investigational medical device (judged as 'related', 'possibly related' or 'relationship not assessable') will be evaluated with respect to type, incidence and intensity up to study termination of each subject. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Joint girth measurement | Baseline | Knee girth measurement as a marker for swelling is taken around the knee at the level of mid-patella as well as 10 centimeters (cm) proximal and distal and documented in cm. |
| Pain intensity | Baseline | Intensity of pain on walking 100 meters will be evaluated on 11-point ordinal scale ranging from '0' (no pain) to '10' (extreme pain). |
| Magnetic Resonance Imaging (MRI) Signal intensity | On Day 180 (plus or minus 14 days) after surgery. | MRI will be assessed with respect to signal intensity of the cartilage repair tissue as 'not isointense', 'isointense' or 'not assessable'. |
| MRI Signal intensity | On Day 360 (plus or minus 14 days) after surgery. | MRI will be assessed with respect to signal intensity of the cartilage repair tissue as 'not isointense', 'isointense' or 'not assessable'. |
| Presence of lesions | On Day 180 (plus or minus 14 days) after surgery. | MRI will be assessed with respect to lesions in the cartilage repair tissue as 'absent', 'minimal', 'moderate', 'severe' or 'not assessable'. |
| All adverse events without causal relationship to the investigational medical device. | Up to 2 years (plus or minus 14 days) after surgery. | Adverse events without causal relationship to the investigational medical device (judged as 'not related') will be evaluated with respect to type, incidence and intensity up to study termination of each subject. |
| Presence of subchondral bone cyst | Baseline | MRI will be assessed with respect to presence of subchondral bone cyst as 'absent', 'minimal', 'moderate', 'severe' or 'not assessable'. |
| Presence of effusion | Baseline | MRI will be assessed with respect to presence of effusion as 'no', 'yes' or 'not assessable'. |
| Knee injury and osteoarthritis outcome score (KOOS) | Baseline | The KOOS score consists of five separate scores calculated for pain, symptoms, activities of daily living, sport and recreational function and knee-related quality of life. Standardized answer options are given (5 Likert boxes) and each question gets a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale. The results can be plotted as an outcome profile. |
| Subjective knee evaluation form | Baseline | The Subjective knee evaluation form of the International Knee Documentation Committee (IKDC) is used to assess symptoms, knee function and sporting activities in patients. The form consists of 18 questions in the domains of symptoms, functioning during activity of daily living and sports, current function of the knee, and participation in work and sports. |
| Presence of subchondral bone oedema | Baseline | MRI will be assessed with respect to presence of subchondral bone oedema as 'absent', 'minimal', 'moderate', 'severe' or 'not assessable'. |
Countries
Germany
Outcome results
None listed